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Background: Vocal cord dysfunction (VCD) is the abnormal adduction of the vocal cords during
inspiration causing extrathoracic airway obstruction. VCD has been described as a confounder of
severeasthma.The influenceofVCDamong less severeasthmaticshasnot beenpreviouslydefined.
Methods: We retrospectively reviewed the medical records of 59 patients with pulmonologist-
diagnosed asthmawhowere referred for videolaryngostroboscopy (VLS) testing from 2006 to 2007.
Results: A total of 44 patients had both asthma and VCD. 15 patients had asthmawithout concom-
itant VCD. Femaleswerepredominant in both groups.Overall, themajority of patients referred for
VLS testing had mild-to-moderate asthma (78%) and 72% of these patients had VCD. Few patients
from either group had ‘‘classic’’ VCD symptoms of stridor or hoarseness. Gastroesophageal reflux
disease (GERD) and rhinitis were common in both groups.
Conclusions: Vocal cord dysfunction occurs across the spectrum of asthma severity. There was
a lack of previously described ‘‘classic’’ VCD symptoms among asthmatics. Symptomswere diverse
and not easily distinguished from common symptoms of asthma, highlighting the need for a high
index of suspicion for VCD in patientswith asthma. Failure to consider and diagnose VCDmay result
inmisleading assumptions about asthma control, and result in unnecessary adjustments of asthma
medications. The high prevalence of GERD raises the question of the role of acid reflux in the
pathogenesis of VCD in asthmatics.
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Over 20 million Americans have asthma which results in
millions of outpatient and emergency room visits, lost work
days, and missed school days annually.1 Recent national
guidelines emphasize assessment and treatment of asthma
symptoms in order to achieve ‘‘asthma control’’.1 The
assessment of asthma control is a complex process and the
current recommended standard instruments primarily rely
on symptom assessment.2 This reliance on asthma symptom
assessment is a significant limitation as there is no reliable
method to ensure non-specific symptoms such as dyspnea or
wheeze represent uncontrolled asthma or are even due to
asthma at all. This is the primary rationale for the recom-
mendation that clinicians be vigilant for common mimics of
asthma or co-morbidities that can present with similar
symptoms and lead to inaccurate assessment of asthma
control.1
Vocal cord dysfunction (VCD) has been previously
described as a mimic of asthma with presenting symptoms
such as stridor, hoarseness and wheezing.3 Vocal cord
dysfunction is the abnormal adduction of the vocal cords
causing airflow limitation. In addition to mimicking asthma,
VCD has also been noted to be present in some patients
with concomitant severe asthma, and current guidelines
recommend evaluating for possible VCD in patients who
present with uncontrolled severe asthma.1,4,5 Whether VCD
is also a significant co-morbidity in patients with less severe
asthma (mild-to-moderate) with the potential to confound
an accurate assessment of asthma control has not been
previously evaluated and was the focus of this study.
We reviewed all cases of co-existent asthma and video-
laryngostroboscopy-documented VCD among patients eval-
uated in a tertiary care asthma clinic to determine the
prevalence of VCD among patients with mild-moderate
asthma and also to determine if there are specific clinical
features that could be used to identify VCD among people
with mild-moderate asthma.
Methods
This study was approved by the Institutional Review Board
at The Ohio State University. 59 patients in total from
the Asthma Center at The Ohio State University Medical
Center with physician-diagnosed asthma were referred for
videolaryngostroboscopy testing during 2006e2007. Recor-
ded data included demographics, asthma severity,1 medical
history, medication use, symptoms, asthma control and
pulmonary function testing results. Medications were
divided into the following categories: oral corticosteroids,
inhaled corticosteroids, long-acting beta-agonists, short-
acting beta-agonists, leukotriene modifiers, mast cell
stabilizers, proton-pump inhibitors, antidepressants, anti-
histamines, and anti-IgE. The symptoms of dyspnea, cough,
wheeze, hoarseness, and stridor were recorded on the
following scale: none, less than two times a week, greater
than two times per week but not daily, daily, and contin-
uous. Night symptoms were recorded on the following
scale: none, less than two times per month, several times
per month, greater than once a week, and nightly. Short-
acting beta-agonist use was recorded as the number oftimes per week. Asthma control was assessed via questions
from the Asthma Therapy Assessment Questionnaire (ATAQ)
questionnaire.6 The ATAQ questionnaire consists of four
questions and is scored on 0e4 scale of asthma control
problems. A score of greater than or equal to two control
problems is associated with worse quality-of-life and
increased health care utilization.
The videolaryngostroboscopy (VLS) was performed
using the Key Elemetrics 9200C system with the 2.4 mm
chip at the tip flexible laryngoscope. All of the studies
were performed by either a Speech Language Pathology
or a Laryngologist. All of the studies were independently
reviewed by an experienced Otolaryngologist/Laryngolo-
gist to confirm the diagnosis. The laryngoscope is passed
in a trans-nasal fashion without anesthesia or sedation
with the patient sitting in an upright position. A contin-
uous pulse oximeter is utilized to monitor oxygen satu-
ration during the exam. The scope is passed just beyond
the velum to observe the patient during quiet respiration
and during connected speech. It is then passed to just
above the epiglottis avoiding the supraglottic structures
in order to prevent reflexive laryngeal constriction. The
larynx is then examined during sustained vowel produc-
tion to look at prolonged expiration and the subsequent
inspiratory effort. Laryngeal motion was then assessed
during commands of oral and nasal breathing. If there is
no evidence of any inappropriate constriction then the
patient is challenged. The challenge consists of exercise
through a stationary recumbent bike, climbing stairs, or
sprinting. The method depends on the history of
provoking factors and the degree of physical conditioning
of the patient. If the bike is used then the scope is left in
position during the challenge. If the other methods are
used to provoke symptoms then the scope is inserted
upon inducing the symptoms. If the exercise does not
induce any abnormal findings then a chemical challenge is
performed using perfumes or non-toxic cleaning
solutions.
The laryngeal movements during the entire are digitally
recorded and are reviewed for appropriate degrees of
abduction during all tasks. Inappropriate constriction is
looked for on inspiration or expiration. In order to be
diagnosed as VCD, the patient must demonstrate abnormal
constriction during the respiratory cycle and also normal
complete abduction during some portion of the exam. If
quiet respirations fail to show the constriction, then the
goal is to induce audible respirations and shortness of
breath and determine the adequacy of the glottic opening
when the symptoms are present.
Results
We found 59 patients with physician-diagnosed asthma who
were referred for videolaryngostroboscopy (VLS) during
2006e2007. A total of 44 (75%) asthmatics had a diagnosis
of vocal cord dysfunction via VLS and 15 (25%) asthmatics
had a negative VLS test.
Comparison of demographics, medical history, family
history, social history and pulmonary function of the 44
patients with both VCD and asthma and the 15 patients with
asthma alone are shown in Table 1. Of the 44 patients with
both asthma and VCD, 80% were female with a mean age of
Table 1 Comparison of characteristics of asthmatic
participants with and without VCD.
No VCD VCD p-Valuea
Count, N 15 44
Age, mean 37.6 43.6 0.234
Male, % 28.6 20.5 0.808
Asthma severity count, N (%)
Intermittent 7 (47) 5 (11) e
Mild persistent 3 (20) 9 (21) e
Moderate persistent 3 (20) 19 (43) e
Severe persistent 2 (13) 11 (25) e
Ht (inches), mean 65.6 64.6 0.457
Wt (lbs), mean 160.9 180.7 0.200
BMI, mean 26.2 29.6 0.150
PMHX
Obstructive sleep apnea, % 0.0 15.9 0.174
GERD, % 93.3 56.8 0.011
Allergic rhinitis, % 73.3 43.2 0.072
Depression, % 26.7 25.0 0.999
Heart disease, % 0.0 2.3 0.999
Sinusitis, % 6.7 11.4 0.999
SocHx
Tobacco use, % 40.0 13.6 0.057
Etoh use, % 60.0 6.8 <0.001
Drug use, % 0.0 2.3 0.999
Medications
Inhaled steroid, % 40.0 70.5 0.062
Oral steroid, % 0.0 2.3 0.999
Leukotriene modifier, % 53.3 43.2 0.558
Long-acting beta-agonist, % 40.0 45.5 0.771
Mast cell stabilizer, % 0.0 4.5 0.999
Short-acting beta-agonist, % 100.0 93.2 0.564
Antidepressant 26.7 22.7 0.738
Proton-pump inhibitor (PPI), % 93.3 75.0 0.160
Antihistamine, % 66.7 34.1 0.037
Anti-IgE, % 0.0 11.4 0.315
Spirometry
FVC, mean 3.64 3.27 0.156
FEV1, mean 2.74 2.52 0.366
FEV1/FVC, mean 74.5 73.9 0.857
a p-Value based on KruskaleWallis for continuous variables
and Fisher’s exact test for categorical variables.
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female with a mean age of 38 years. There were no
significant differences in any demographic factors between
the 44 patients with asthma and VCD when compared with
the 15 patients with asthma and a negative VLS test. 33 of
44 (75%) patients with asthma and VCD had mild-to-
moderate asthma, while 13 of 15 (87%) patients with
asthma and no VCD had mild-to-moderate asthma. Overall,
of the 46 patients with mild-to-moderate asthma referred
for VLS testing from both groups, 33 patients had VCD
(72%).
Patients with asthma but no VCD were significantly more
likely to report a past medical history of GERD (pZ 0.011)
and to drink alcohol (p< 0.001). They were also more likelyto report allergic rhinitis but these differences were not
statistically significant. Conversely, patients with both
asthma and VCD were more likely to have obstructive sleep
apnea (OSA) although the differences also were not
significant.
The majority of patients were on a daily asthma
controller with 71% of patients with both asthma and VCD
on at least one controller versus 53% for asthmatics without
VCD. Only one patient in either group was taking oral
steroids. Almost all patients were using a short-acting beta-
agonist inhaler. Asthmatics without VCD were more likely to
be on proton-pump inhibitors (PPI) (93% versus 57%,
pZ 0.011) and anti-histamines than asthmatics with VCD
(67% versus 34%, pZ 0.037).
Table 2 shows characteristics of the 44 patients with
asthma and VCD after stratification by asthma severity. The
prevalence of rhinitis ranged from 37% to 56%. GERD was
also very common and occurred more often in those with
moderate or severe asthma (63%, 64% respectively), as
compared to intermittent or mild persistent (40%, 44%,
respectively). Patients with higher BMI trended toward
more severe asthma and higher prevalence rates of GERD.
Patients with more severe asthma were older and were
more likely to be depressed. There were no significant
differences in medication use after stratification by asthma
severity in the 44 patients with both asthma and VCD
(Table 3).
As demonstrated in Fig. 1, the majority of patients with
both asthma and vocal cord dysfunction (75%) had mild-to-
moderate asthma, specifically 11% intermittent, 21% mild
persistent, and 43% moderate persistent. Only 25% of
patients with asthma and VCD were classified as having
severe persistent asthma per NIH guidelines.1 Data for the
15 patients with asthma alone is shown in Fig. 1 as well. 87%
of these patients had mild-to-moderate asthma.
Table 4 compares symptoms and asthma control
between the 44 patients with VCD and asthma and the 15
patients with asthma alone. Patients with both asthma and
VCD had more cough (pZ 0.002), wheeze (pZ 0.019), and
dyspnea (p< 0.001) than asthmatics without VCD.
However, there were no differences in the prevalence of
‘‘classic’’ VCD symptoms of hoarseness and stridor between
the two groups. Overall, the 44 patients with asthma and
VCD had significantly more asthma control problems based
on ATAQ scores than the 15 patients with asthma alone.
(pZ 0.001).
Discussion
Vocal cord dysfunction has previously been described as
a mimic of asthma3 and is known to co-exist in patients with
severe asthma. Therefore, physicians commonly refer
patients with ‘‘classic’’ symptoms of stridor or hoarseness
for VLS testing and are more likely to consider VCD in
patients with refractory asthma.3 We found that in addition
to severe asthma, vocal cord dysfunction occurs frequently
in patients with mild-to-moderate asthma.
We also determined the ‘‘classic’’ symptoms of vocal cord
dysfunction of hoarseness and stridor occur overall infre-
quently in patients with both VCD and asthma and do not
distinguish asthmatics with VCD from those without VCD. In
fact, patients with both VCD and asthma present with non-
Table 2 Characteristics of participants with VCD and asthma stratified by asthma severity.
Total Severe Moderate Mild-persistent Intermittent p-Value
Count, N (% total cohort) 44 11 (25.0) 19 (43.2) 9 (20.5) 5 (11.4)
Age, mean 43.6 53.5 45.7 32.7 34.0 0.033
Male, % 20.5 27.3 21.1 22.2 0.0
Body Mass Index, mean (kg/m2) 29.9 35.5 30.1 25.2 24.7 0.087
Past medical history
Obstructive sleep apnea, % 15.9 36.4 15.8 0.0 0.0 0.143
GERD, % 56.8 63.6 63.2 44.4 40.0 0.681
Allergic rhinitis, % 43.2 45.5 36.8 55.6 40.0 0.871
Depression, % 25.0 63.6 10.5 11.1 20.0 0.008
Heart disease, % 2.3 9.1 0.0 0.0 0.0 0.568
Sinusitis, % 11.4 9.1 5.3 33.3 0.0 0.163
Family history
Asthma, % 15.9 18.2 21.1 11.1 0.0 0.937
Depression, % 0.0 0.0 0.0 0.0 0.0 e
Allergic rhinitis, % 2.3 0.0 5.3 0.0 0.0 1.000
Social history
Tobacco use, % 13.6 18.2 15.8 11.1 0.0 1.000
Alcohol use, % 6.8 0.0 15.8 0.0 0.0 0.442
Illicit drug use, % 2.3 0.0 5.3 0.0 0.0 1.000
Employed, % 63.6 63.6 63.2 55.6 80.0 0.914
Spirometry 0.568
FVC, mean (liters) 3.27 2.63 3.19 3.95 3.95 0.871
FEV1, mean (liters) 2.52 1.80 2.44 3.30 2.98 0.183
FEV1/FVC, mean % 73.9 66.0 74.6 78.5 80.1 0.418
p-Value based on KruskaleWallis for continuous variables and Fisher’s exact test for categorical variables.
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dyspnea, cough and wheezing. This may result in two
consequences. One, VCD may be underdiagnosed in patients
with asthma as these symptoms may be misinterpreted as
manifestations of poor asthma control. Two, clinicians may
incorrectly attribute symptoms of VCD to poor asthma
control and escalate asthma therapy. Our data show that
patients with VCD and asthma have more asthma control
problems as assessed by validated asthma questionnaires,
however, it is not clear whether these symptoms are fromTable 3 Medications used by participants with VCD and asthma
Medications Total Severe M
Count, N (%) 44 (100) 11 (25.0) 19
Inhaled steroid, % 70.5 81.8 78
Oral steroid, % 2.3 9.1 0.
Leukotriene modifier, % 43.2 54.5 42
Long-acting beta-agonist, % 45.5 72.7 42
Mast cell stabilizer 4.5 9.1 0.
Any controller medicine, % 75.0 81.8 89
Short-acting beta-agonist, % 93.2 100.0 94
Antidepressant 22.7 45.5 10
Proton-pump inhibitor, % 75.0 72.7 78
Antihistamine, % 34.1 27.3 36
Anti-IgE, % 11.4 18.2 10
p-Value based on KruskaleWallis for continuous variables and Fisher’asthma or whether theymay represent VCD instead. Overall,
our data highlight the need for physicians to have a high
index of suspicion for VCD in poorly controlled asthmatics,
independent of the level of asthma severity.
GERD was a frequent co-morbidity in both patients with
asthma and VCD and with asthma alone. However, 71% of
the patients had laryngeal edema from GERD on VLS testing
which demonstrates a significant number of patients with
inadequately treated or undiagnosed GERD. These findings
are consistent with recent data documenting a highstratified by asthma severity.
oderate Mild-persistent Intermittent p-Value
(43.2) 9 (20.5) 5 (11.4)
.9 44.4 60.0 0.223
0 0.0 0.0 0.568
.1 33.3 40.0 0.871
.1 33.3 20.0 0.183
0 11.1 0.0 0.063
.5 44.4 60.0 0.418
.7 100.0 60.0 0.090
.5 11.1 40.0 0.850
.9 77.8 60.0 0.809
.8 44.4 20.0 0.912
.5 11.1 0.0 0.223
s exact test for categorical variables.
Figure 1 Distribution of patients in each group stratified by
asthma severity.
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previously suggested that laryngeal reflux may be causally
related to the development of VCD in some patients,8,9 and
thus might be an underlying factor in the high prevalence of
VCD among asthmatics. Small studies in patients with VCD,
but not asthma, treated with proton-pump inhibitors and
laryngeal control therapy showed an improvement in
cough.8,9 Therefore, a trial of proton-pump inhibitors is
likely appropriate in those patients that have any type of
GERD symptoms or laryngeal edema documented on VLS.
Diagnosing vocal cord dysfunction not only requires
a high index of suspicion, it also requires access to
specialized videolaryngostroboscopy testing to definitively
document VCD. It is important to note that VLS testing can
fail to document VCD even in patients who are known to
have VCD.3,10 These false negative VLS tests occur primarily
because VCD is paroxysmal in most cases; therefore,
provocation with exercise or noxious stimuli is commonly
utilized at our center to increase the likelihood of capturing
an episode of VCD during VLS testing.
In our study, patients with more severe asthma based on
guidelines had worse asthma control as measured by ATAQ
scores which is not surprising. However, it is unclear how
VCD symptoms confound the assessment of asthma control.Table 4 Comparison of asthma symptoms and asthma
control.
No VCD VCD p-Valuea
Symptomsb
Count, N 15 44
Dyspnea, mean 0.87 1.77 <0.001
Night Sx, mean 1.00 1.11 0.256
Short B-agonist use, mean 1.27 1.70 0.377
Cough, mean 0.60 1.57 0.002
Wheeze, mean 0.53 1.18 0.019
Hoarseness, % 0.20 0.20 0.999




a p-Value based on Fisher’s exact test.
b Mean symptoms, scale is 0e4 representing 0Z none,
1Z<2/week, 2Z>2/week, 3Z daily, 4Z continuous.Furthermore, whether diagnosis and treatment of VCD has
any impact on asthma control is unknown. A common
treatment for VCD is laryngeal control therapy which is
typically provided by speech language pathologists This is
a noninvasive treatment that has provided modest
improvement in VCD,8,9,11,12 but whether it impacts asthma
control has not been established. Future research should
investigate the long-term outcomes of patients with
concomitant asthma and VCD and whether treatment of
VCD improves asthma control in these patients.
Our study is limited by its retrospective design and
relatively small sample size. There is certainly a possibility
for selection bias as our patients were managed at
a tertiary referral center; however, the large percentage of
mild-to-moderate asthmatics would suggest that the data is
generalizable to most populations of asthmatics. Our defi-
nition of VCD was dependent upon a positive VLS test which
likely underestimated the population who in fact has VCD
given the known false negative rate for VLS.
Conclusions
Vocal cord dysfunction occurs across the spectrum of
asthma severity and is prevalent in mild-to-moderate
asthmatics. Symptoms previously described in association
with VCD such as stridor or hoarseness are not common in
patients with both asthma and VCD. Patients with VCD and
asthma report increases in non-specific symptoms and
worse asthma control as measured by the ATAQ question-
naire. It is unclear if these patients truly have more poorly
controlled asthma or if the increase in the ATAQ scores in
patients with more severe asthma is due to the presence
of VCD. Future prospective studies are needed to deter-
mine establish the impact of the diagnosis and treatment
of VCD on asthma control and asthma-related quality-of-
life.
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